NeuroPace, Inc. (NPCE)

NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04

$13.34+8.37%

Close 2026-11-04 · 1-day change

NeuroPace, Inc. (NPCE) Outlook: What's Priced In | QuarterlyIQ

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge NeuroPace, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for NPCE yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Limit adjusted EBITDA loss to no worse than $9.5 million	The company improved its adjusted EBITDA loss guidance to about negative $9 million.	Intact	Adjusted EBITDA loss exceeds $9.5 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Adjusted EBITDA guidance improved from a range of ($9.0) million to ($10.0) million to ($8.5) million to ($9.5) million for 2026. This reflects management's focus on cost control and improved profitability, showing progress on this priority.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.28

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Limit adjusted EBITDA loss to no worse than $9.5 millionDirect metric needs a verified mapping
Maintain gross margin between 81.5% and 82.5%Gross margin: 82.83%
Achieve full-year 2026 revenue of at least $99 millionRevenue: $22.826M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-36.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

NeuroPace, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a smaller-cap growth business with elevated risk, not a proven profitable compounder. The long-term thesis is on watch: management has delivered on revenue and gross-margin priorities, while recent financial performance remains weak versus its industry cohort.

What's priced into NeuroPace, Inc.

The valuation model indicates a durable premium of 1.56 versus peers, while the expectations gap is negative at -0.43. That suggests expectations may be ahead of the evidence, though model confidence is low and the priced-in assessment is marked justified with low fragility.

What the fundamentals likely do

Near term, 2026 revenue guidance has risen to $99 million to $101.5 million, and gross-margin guidance remains high. Adjusted EBITDA guidance has improved, but the company remains loss-making and recent financial performance is weak; smaller size and a history of a deep miss add risk despite a quiet near-term miss watch.

What NeuroPace, Inc. hinges on

The multi-year view depends on NPCE sustaining its raised guidance and converting revenue growth into better profitability. A guidance reversal would damage management credibility, while weaker jobs data could weigh on healthcare names; continued strong results and guidance from sector bellwethers would support the sector backdrop.

Bottom line

Over the next 1 to 3 years, NPCE’s thesis is a growth-and-margin improvement story with meaningful execution risk, and recent weakness has not freshly broken the thesis. The evidence is mixed, with low confidence in the valuation model. Not investment advice.

Development preview · refreshed Nov 5, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.34	$123,266,108	5 / 6
2026-07-25	$-0.34	$123,266,108	5 / 6
2026-07-26	$-0.37	$123,414,318	6 / 7
2026-07-27	$-0.37	$123,414,318	6 / 7
2026-07-28	$-0.30	$123,247,720	7 / 8
2026-07-29	$-0.37	$123,414,318	6 / 7
2026-07-30	$-0.30	$123,247,720	7 / 8
2026-07-31	$-0.29	$123,437,080	8 / 9
2026-08-01	$-0.37	$123,412,752	6 / 7
2026-08-02	$-0.29	$123,437,080	8 / 9
2026-08-03	$-0.37	$123,412,752	6 / 7
2026-08-04	$-0.37	$123,412,752	6 / 7
2026-08-05	$-0.37	$123,412,752	6 / 7
2026-08-06	$-0.29	$123,437,080	8 / 9
2026-08-07	$-0.37	$123,412,752	6 / 7
2026-08-08	$-0.29	$123,437,080	8 / 9
2026-08-09	$-0.29	$123,437,080	8 / 9
2026-08-10	$-0.37	$123,412,752	6 / 7
2026-08-12	$-0.37	$123,412,752	6 / 7
2026-08-13	$-0.37	$123,412,752	6 / 7
2026-08-14	$-0.37	$123,412,752	6 / 7
2026-08-15	$-0.37	$123,412,752	6 / 7
2026-08-16	$-0.37	$123,412,752	6 / 7
2026-08-17	$-0.37	$123,412,752	6 / 7
2026-08-18	$-0.37	$123,412,752	6 / 7
2026-08-19	$-0.37	$123,412,752	6 / 7
2026-08-20	$-0.33	$122,344,051	6 / 7
2026-08-21	$-0.33	$122,344,051	6 / 7
2026-08-22	$-0.33	$122,344,051	6 / 7
2026-08-23	$-0.33	$122,344,051	6 / 7
2026-08-24	$-0.33	$122,344,051	6 / 7
2026-08-25	$-0.33	$122,344,051	6 / 7
2026-08-26	$-0.33	$122,344,051	6 / 7
2026-08-27	$-0.33	$122,344,051	6 / 7
2026-08-28	$-0.33	$122,344,051	6 / 7
2026-08-29	$-0.33	$122,344,051	6 / 7
2026-08-30	$-0.33	$122,344,051	6 / 7
2026-08-31	$-0.33	$122,344,051	6 / 7
2026-09-01	$-0.33	$122,344,051	6 / 7
2026-09-02	$-0.33	$122,344,051	6 / 7
2026-09-03	$-0.33	$122,344,051	6 / 7
2026-09-04	$-0.33	$122,344,051	6 / 7
2026-09-05	$-0.33	$122,344,051	6 / 7
2026-09-06	$-0.33	$122,344,051	6 / 7
2026-09-07	$-0.33	$122,344,051	6 / 7
2026-09-08	$-0.33	$122,344,051	6 / 7
2026-09-09	$-0.33	$122,344,051	6 / 7
2026-09-10	$-0.33	$122,348,162	6 / 7
2026-09-11	$-0.33	$122,348,162	6 / 7
2026-09-12	$-0.33	$122,348,162	6 / 7
2026-09-13	$-0.33	$122,348,162	6 / 7
2026-09-14	$-0.33	$122,348,162	6 / 7
2026-09-15	$-0.33	$122,348,162	6 / 7
2026-09-16	$-0.33	$122,344,184	6 / 7
2026-09-17	$-0.33	$122,344,184	6 / 7
2026-09-18	$-0.33	$122,344,184	6 / 7
2026-09-19	$-0.31	$122,259,766	6 / 7
2026-09-20	$-0.31	$122,259,766	6 / 8
2026-09-21	$-0.31	$122,259,766	6 / 8
2026-09-22	$-0.31	$122,259,766	6 / 8
2026-09-23	$-0.31	$122,259,766	6 / 8
2026-09-24	$-0.31	$122,259,766	6 / 8
2026-09-25	$-0.31	$122,259,766	6 / 8
2026-09-26	$-0.31	$122,259,766	6 / 8
2026-09-27	$-0.31	$122,259,766	6 / 8
2026-09-28	$-0.31	$122,259,766	6 / 8
2026-09-29	$-0.31	$122,259,766	6 / 8
2026-09-30	$-0.31	$122,259,766	6 / 8
2026-10-01	$-0.31	$122,259,766	6 / 8
2026-10-02	$-0.31	$122,259,766	6 / 8
2026-10-03	$-0.31	$122,259,766	6 / 8
2026-10-04	$-0.31	$122,259,766	6 / 8
2026-10-05	$-0.31	$122,259,766	6 / 8
2026-10-06	$-0.31	$122,259,766	6 / 8
2026-10-07	$-0.31	$122,259,766	6 / 8
2026-10-08	$-0.31	$122,259,766	6 / 8
2026-10-09	$-0.31	$122,259,766	6 / 8
2026-10-10	$-0.29	$122,259,766	6 / 8
2026-10-11	$-0.29	$122,259,766	6 / 8
2026-10-12	$-0.29	$122,259,766	6 / 8
2026-10-13	$-0.29	$122,259,766	6 / 8
2026-10-14	$-0.29	$122,260,065	6 / 8
2026-10-15	$-0.29	$122,260,065	6 / 8
2026-10-16	$-0.29	$122,260,065	6 / 8
2026-10-17	$-0.29	$122,260,065	6 / 8
2026-10-18	$-0.28	$121,947,800	6 / 8
2026-10-19	$-0.28	$121,947,800	6 / 8
2026-10-20	$-0.28	$121,947,800	6 / 8
2026-10-21	$-0.28	$121,947,800	6 / 8
2026-10-22	$-0.28	$121,947,800	6 / 8
2026-10-23	$-0.28	$121,947,800	6 / 8
2026-10-24	$-0.28	$121,947,800	6 / 8
2026-10-25	$-0.28	$121,947,800	6 / 8
2026-10-26	$-0.28	$121,947,800	6 / 8
2026-10-27	$-0.28	$121,947,800	6 / 8
2026-10-28	$-0.28	$121,949,009	6 / 8
2026-10-29	$-0.28	$121,947,800	6 / 8
2026-10-30	$-0.28	$121,947,800	6 / 8
2026-10-31	$-0.28	$121,947,800	6 / 8
2026-11-01	$-0.28	$121,947,800	6 / 8
2026-11-02	$-0.28	$121,947,800	6 / 8
2026-11-03	$-0.28	$121,947,800	6 / 8
2026-11-04	$-0.28	$121,947,800	6 / 8

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	8	0	0
2026-07-01	9	0	0
2026-08-01	9	0	0
2026-09-01	10	0	0
2026-10-01	10	0	0
2026-11-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Oct 6–Nov 4 · 0 recorded

What could strengthen or challenge NeuroPace, Inc.’s outlook?

Price, analyst earnings & P/E reference

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

NeuroPace, Inc. outlook in detail

What kind of bet this is

What's priced into NeuroPace, Inc.

What the fundamentals likely do

What NeuroPace, Inc. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line